Carlos Gonzalez, MD
Nephrology · Montebello, CANPI 1891722369
Payments from drug & device makers
Across 582 payments — averaging $491.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$202K
- GSK$56K
- Gilead$12K
- CSL Behring$6K
- Amgen$2K
- Ardelyx, Inc.$884
- plus $7K from 24 others
Across 9 payments — averaging $98.45 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$886
What the payments were for
- Consulting fees$1,56011%
- Travel & lodging$2,74819%
- Food & beverage$9,72068%
- Education$1651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 185 | $201,950 |
| GSK | 45 | $56,347 |
| Gilead | 5 | $12,395 |
| CSL Behring | 17 | $5,813 |
| Amgen(2 entities) | 74 | $1,792 |
| Ardelyx, Inc. | 6 | $884 |
| AstraZeneca | 25 | $877 |
| Intuitive Surgical | 3 | $780 |
| Calliditas Therapeutics US Inc. | 27 | $584 |
| Bayer | 24 | $577 |
| Fresenius USA Marketing, Inc. | 30 | $535 |
| Travere Therapeutics, Inc. | 29 | $430 |
| ANI Pharmaceuticals, Inc. | 21 | $390 |
| Vifor Pharma, Inc. | 13 | $379 |
| Mallinckrodt Hospital Products Inc. | 14 | $378 |
| Otsuka America Pharmaceutical, Inc. | 12 | $343 |
| Novartis | 9 | $292 |
| OPKO Pharmaceuticals, LLC | 10 | $258 |
| Outset Medical Inc | 1 | $242 |
| Aurinia Pharma U.S., Inc. | 8 | $183 |
| Boehringer Ingelheim | 5 | $114 |
| Novo Nordisk | 5 | $111 |
| Lilly USA, LLC | 5 | $110 |
| Baxter Healthcare | 1 | $96 |
| Scpharmaceuticals Inc. | 2 | $52 |
| Apellis Pharmaceuticals, Inc. | 2 | $42 |
| Medtronic | 1 | $33 |
| Sanofi | 1 | $29 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$286,053 in reported general payments places this provider in the 90th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 471 | $313,352 |
| VelphoroSucroferric Oxyhydroxide | 60 | $185,583 |
| LokelmaSodium Zirconium Cyclosilicate | 181 | $161,664 |
| FarxigaDapagliflozin Propanediol | 229 | $146,937 |
| DapagliflozinDapagliflozin Propanediol | 138 | $73,711 |
| VeltassaPatiromer Calcium Sorbitex | 61 | $68,063 |
| XphozahTenapanor Hcl | 16 | $48,767 |
| JardianceEmpagliflozin | 35 | $29,048 |
| JanuviaSitagliptin Phosphate | 39 | $26,531 |
| RayaldeeCalcifediol | 18 | $20,872 |
| Sevelamer Hcl | 23 | $19,837 |
| AuryxiaFerric Citrate | 14 | $19,760 |
| ProcritEpoetin Alfa | 23 | $15,425 |
| Sevelamer Carbonate | 80 | $12,880 |
| RetacritEpoetin Alfa-Epbx | 22 | $8,210 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $577 | $313,352471 claims |
| AstraZenecaLokelma, Farxiga | $877 | $308,600410 claims |
| Fresenius USA Marketing, Inc.Velphoro | $535 | $185,58360 claims |
| Boehringer IngelheimJardiance | $114 | $29,04835 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $258 | $20,87218 claims |
| Akebia Therapeutics IncAuryxia | $201,950 | $19,76014 claims |
| AmgenEpogen | $1,792 | $3,76611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,341 nephrology providers in California.
Other nephrology in Montebello
- Anjay RastogiLos Angeles$6.3M
- Aamir JamalSan Dimas$5.5M
- Mohamed El-ShahawyLos Angeles$4.4M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
- Sohan DuaNorthridge$3.2M
- Richard LafayetteStanford$3M
- Anant DesaiGranada Hills$2.9M
- Glenn ChertowStanford$2.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.